CKDXF OTC
Ceryvyn Therapeutics Limited
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: -97.7%
1Y: -97.7%
3Y: -97.6%
5Y: -99.1%
$0.01
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$667
-97.4% ▼
5Y CAGR: -62.7%
Gross Profit
$667
+101.0% ▲
Operating Income
-$8M
+94.9% ▲
Net Income
$221M
+235.5% ▲
EPS (Diluted)
$0.16
+223.1% ▲
EBITDA
-$8M
+93.3% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $125K | $161K | $125K | $25K | $667 |
| YoY Growth | +35.9% | +28.9% | -22.6% | -79.9% | -97.4% |
| Cost of Revenue | $232K | $250K | $103K | $92K | $0 |
| Gross Profit | -$107K | -$89K | $22K | $25K | $667 |
| Gross Margin | -85.9% | -55.4% | 17.7% | 100.0% | 100.0% |
| R&D Expenses | $108M | $182M | $176M | $127M | $2M |
| SG&A Expenses | $25M | $42M | $15M | $21M | $5M |
| Operating Expenses | $133M | $223M | $192M | $156M | $8M |
| Operating Income | -$133M | -$223M | -$192M | -$156M | -$8M |
| Operating Margin | -106576.0% | -138648.0% | -153885.4% | -623048.0% | -1194700.0% |
| Interest Expense | $0 | $13M | $30M | $46M | $8M |
| Income Before Tax | -$137M | -$221M | -$230M | -$170M | $220M |
| Tax Expense | -$9M | -$9M | -$9M | -$7M | -$139K |
| Net Income | -$128M | -$212M | -$220M | -$163M | $221M |
| Net Margin | -102353.7% | -131469.8% | -176665.7% | -651164.0% | 33044499.9% |
| EPS (Diluted) | $-0.34 | $-0.45 | $-0.35 | $-0.13 | $0.16 |
| EBITDA | -$99M | -$223M | -$199M | -$123M | -$8M |
| Shares Outstanding | 373M | 470M | 638M | 1.22B | 1.35B |